Biomarkers

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Alzheimer's Disease (AD) is a progressive neurodegenerative disorder with complex etiology.
• Current AD research often uses single omics approaches, limiting comprehensive understanding.
• Pathological changes in AD begin decades before symptom onset.

Purpose of the Study:

• To investigate the etiology and pathogenesis of Alzheimer's Disease.
• To integrate metabolomics and methylation analysis for deeper insights into AD.
• To explore the relationship between epigenetic changes and metabolic alterations in AD.

Main Methods:

• Utilized targeted LC-MS/MS and 1H NMR for metabolite profiling.
• Employed Illumina Infinium Methylation EPIC Bead Chip assay for methylation analysis.
• Analyzed post-mortem brain samples from AD, mild-AD, and control groups.

Main Results:

• Identified significant differences in metabolite concentrations between AD/mild-AD and control groups.
• Detected differentially methylated CpGs in individuals with AD and mild-AD compared to controls.
• Revealed upregulated inflammatory, serotonergic, and sphingolipid metabolic pathways in mild-AD.

Conclusions:

• Demonstrated an intricate relationship between methylation changes and metabolite concentrations in AD.
• Highlighted the utility of integrating metabolomics and epigenetics for studying AD.
• Emphasized the potential of multi-omics approaches for understanding AD pathogenesis.